A CLINICAL TRIAL TWO COMPARE TO TREATMENT SCHEDULES OF CONCURRENT CHEMORADIATION IN LOCALLY ADVANCED CANCER OF CERVIX.

A PROSPECTIVE STUDY ON CONCURRENT CHEMORADIATION IN CARCINOMA CERVIX - WEEKLY VERSUS DAILY CISPLATIN SCHEDULE

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2010/091/000194

Enrollment

Registered

2010-03-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: WEEKLY CISPLATINUM WITH RADIATION: 40mg/M2 weekly once, concurrent radiation Control Intervention1: DAILY CISPLATINUM WITH RADIATION: 6mg/m2 daily once, concurrent radiation

Eligibility

Inclusion criteria

Inclusion criteria: 1. women with biopsy proved uterine cancer, less than or equal to 70 yeras of age, locally advancer uerine cancer, WHO P.S 0-1, Normal CBC, LFT, RFT.

Exclusion criteria

Exclusion criteria: PRIOR CHEMOTHERAPY OR RADIATION, PARA AORTIC LYPH NODE INVOLVEMENT, DISTANT METASTASIS

Design outcomes

Primary

Measure	Time frame
1. Clinical response& local control of disease, disease free survival. 2. Delayed toxicityTimepoint: 3 years may extend to 5 years	—

Secondary

Measure	Time frame
ACUTE TOXICITY & TOLERABILITYTimepoint: 1 YEAR	—

Countries

India

Contacts

Public ContactDR.ARAVINDH.S.ANAND

anandrt2006@yahoo.com4772126336

Outcome results